Despite the fact that the ethnic differences between Asian and Caucasian populations in response to immune checkpoint inhibitor therapy in non-small-cell lung cancer remain controversial [43], it has been claimed that characteristics of Asian patients, including higher EGFR mutation rates, hepatitis B virus infection, and related immunotoxicity, are contributing factors [44]. This evidence concerns the gene EGFR and hepatitis B virus infection.